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EAACI Guidelines on Allergen Immunotherapy: Prevention of allergy 
 
Pediatr Allergy Immunol 
 
Abstract  
Allergic diseases are common and frequently coexist. Allergen immunotherapy (AIT) is a disease-
modifying treatment for IgE-mediated allergic disease with effects beyond cessation of AIT that may 
include important preventive effects. The European Academy of Allergy and Clinical Immunology 
(EAACI) has developed a clinical practice guideline to provide evidence-based recommendations for 
AIT for prevention of i) development of allergic comorbidities in those with established allergic 
diseases, ii) development of first allergic condition and iii) allergic sensitization. This guideline has 
been developed using the Appraisal of Guidelines for Research & Evaluation (AGREE II) framework, 
which involved a multi-disciplinary expert working group, a systematic review of the underpinning 
evidence and external peer-review of draft recommendations. Our key recommendation is that a three 
year course of subcutaneous or sublingual AIT can be recommended for children and adolescents 
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with moderate to severe allergic rhinitis (AR) triggered by grass/birch pollen allergy to prevent asthma 
for up to two years post-AIT in addition to its sustained effect on AR symptoms and medication. Some 
trial data even suggest a preventive effect on asthma symptoms and medication more than two years 
post AIT. We need more evidence concerning AIT for prevention in individuals with AR triggered by 
house dust mites or other allergens and for the prevention of allergic sensitization, the first allergic 
disease or for prevention of allergic co-morbidities in those with other allergic conditions. Evidence for 
the preventive potential of AIT as disease modifying treatment exists but there is an urgent need for 
more high-quality clinical trials. 
 
Keywords: Allergen immunotherapy, allergic diseases, allergy, atopy, prevention, sensitization, 
AGREE II, asthma, allergic rhinitis; atopic dermatitis/eczema 
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Abbreviations:  
AD: Atopic dermatitis (atopic eczema) 
AIT: Allergen immunotherapy 
AR: Allergic rhinitis / Allergic rhinoconjunctivitis 
ARIA: Allergic Rhinitis and its Impact of Asthma 
CBA: Controlled before and after study 
EMA: European Medicines Agency 
HDM: House dust mite 
OAS: Oral allergy syndrome 
Qol: Quality of life 
RCT: Randomized controlled trial 
SCIT: Subcutaneous immunotherapy 
SLIT: Sublingual immunotherapy 
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SPT: Skin prick test 
SR: Systematic Review 
WAO: World Allergy Organization 
 
Introduction  
Allergic diseases are among the commonest chronic diseases and encompass atopic 
eczema/dermatitis (AD), asthma, allergic rhinitis and allergic rhinoconjunctivitis (both from here 
onward referred to as AR), food allergy and venom allergy [1-5]. They frequently start in early 
childhood and continue throughout adulthood. Allergies can cause a considerable burden to 
individuals leading to impaired quality of life [6]. At a societal level, they cause additional costs, 
particularly in terms of healthcare utilization, reduction in economic productivity and impacting on 
activities of daily living. The latter may include loss of school days, work absence, presenteeism and 
early retirement [7;8]. For allergic asthma and AR, many patients respond well to pharmacotherapy, 
whereas others do not or need treatment with more than one product [9]. However, there is good 
evidence for the clinical efficacy of allergen immunotherapy (AIT) for AR, allergic asthma and 
moderate to severe venom allergy [10-12] with many patients responding to therapeutic AIT, leading 
to a sustained reduction in symptoms and requirement for symptomatic treatment.  
AIT is considered a disease-modifying intervention in IgE-mediated allergic disease, with both a 
therapeutic, even beyond cessation of AIT [10-12], and the potential for a preventive effect [13-16]. It 
has been shown that children with AR have a 3-fold increased risk of developing asthma [17;18] and 
that childhood AD and AR are strongly associated with the incidence and persistence of adult atopic 
asthma and with allergic asthma persisting into adulthood [19]. Studies assessing the long-term 
effectiveness of AIT in children with AR indicate that AIT might reduce the risk of developing asthma 
[20-23]. AIT has the potential to induce immunological changes that result in immune modification [14]. 
Therefore, AIT should be considered as a preventive strategy in the treatment of allergic diseases. 
This Guideline has been developed by the European Academy of Allergy and Clinical Immunology 
(EAACI) Taskforce on AIT for Allergy Prevention and form part of the EAACI Guidelines on Allergen 
Immunotherapy. The aim is to provide evidence-based recommendations for the use of AIT for 
prevention of i) further allergic co-morbidities in those with established allergic disease, ii) first allergic 
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disease and iii) development of allergic sensitization. This Guideline does not cover prevention of 
symptoms, exacerbations or progression of already existing allergic disease since this is included in 
other guidelines in this series. Likewise it does not cover weaning and dietetic strategies, which are 
considered in the ‘EAACI food allergy and anaphylaxis guidelines: Primary prevention of food allergy’ 
[24]. Definition of key terms are described in Box 1. 
The primary audience for this Guideline are clinical allergists (specialists and subspecialists). It may 
also provide guidance for other healthcare professionals e.g., physicians, nurses and pharmacists 
working across a range of primary, secondary and tertiary care settings managing patients with 
allergic diseases and healthy individuals at risk of developing allergic diseases. 
Box 1. Key terms 
Allergic asthma Typical symptoms of asthma (wheezing, cough, dyspnea, chest 
tightness with evidence of reversibility) induced upon exposure to an 
allergen together with the proof of immunological sensitization to that 
allergen 
Allergic conjunctivitis Inflammation of the conjunctiva characterized by watery, itchy, red 
eyes induced upon exposure to an allergen together with the proof of 
immunological sensitization to that allergen 
Allergic diseases Atopic dermatitis (eczema) (AD), food allergy (FA), allergic asthma, 
allergic rhinitis/conjunctivitis (AR) and venom allergy at any age 
Allergic rhinitis  Inflammation of the nasal mucosa resulting in at least two nasal 
symptoms: rhinorrhoea, blockage, sneezing or itching induced 
upon exposure to an allergen together with the proof of immunological 
sensitization to that allergen 
AIT (Allergen 
immunotherapy) 
Repeated allergen exposure at regular intervals to modulate immune 
response to reduce symptoms and need for medication for clinical 
allergies and to prevent the development of new allergies and asthma 
(adapted from European Medicines Agency (EMA)). This is also 
sometimes known as allergen specific immunotherapy, desensitization, 
hyposensitization and allergy vaccination*  
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 Subcutaneous immunotherapy (SCIT): Form of AIT where the 
allergen is administered as subcutaneous injections 
 Sublingual immunotherapy (SLIT): Form of AIT where the 
allergen is administered under the tongue with formulation as 
drops or tablets 
Healthy individuals Individuals with or without IgE sensitization, but without any 
manifestations of current allergic disease 
Prevention Prevention of the development of a new sensitization or new allergic 
disease in healthy individuals without sensitizations, in healthy 
individuals with sensitizations and in those who already have an 
allergic disease 
Short-term prevention: preventive effect assessed within a two year 
window post-AIT 
Long-term prevention: preventive effect maintained after at least two 
years post-AIT 
In this document, specific treatment effects such as effect on 
exacerbations and progression of the disease, including long-term 
effects, are not regarded as prevention. 
Sensitization Detectable specific  IgE antibodies, either by means of SPT or 
determination of specific-IgE antibody levels in a serum sample 
* Dietary interventions in infants aimed at the prevention of food allergy are not covered in 
this Guideline: they form part of the ‘EAACI food allergy and anaphylaxis guidelines. Primary 
prevention of food allergy’ https://www.ncbi.nlm.nih.gov/pubmed/24697491 [24]. 
 
Methods 
Development of the Guideline has been informed by a formal systematic review [25] and meta-
analysis of AIT for prevention of allergy [25] with SR principles being used to identify additional 
evidence, where necessary.  
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This Guideline was produced using the Appraisal of Guidelines for Research & Evaluation (AGREE II) 
approach [26;27]. This structured method for guideline production is designed to ensure appropriate 
representation of the full range of stakeholders, an exhaustive search for and critical appraisal of the 
relevant literature, a systematic approach to the formulation and presentation of recommendations, 
and steps to ensure that the risk of bias is minimized at each step of the process. The process began 
in April 2015 with detailed face-to-face discussions agreeing on the process and the key clinical areas 
to address, followed by face-to-face and web-conferences in which professional and lay 
representatives participated.  
Clarifying the scope and purpose of the guidelines 
The scope of this EAACI Guideline is multifaceted, providing recommendations that assist clinicians in 
the optimal use of AIT for the prevention of development of allergic disease in the management of 
individuals with, or at risk for, allergic disease, and identifying gaps for further research. The Guideline 
builds on a SR conducted to summarise the evidence base in relation to these aims (Box 2) [25]. 
Box 2: Summary of the aim and outcomes in the supporting systematic review [25] 
Aim:  
To provide the evidence basis for formulating clinical practice guidelines for the use of AIT as preventive 
therapeutic intervention in allergy. This will be based on a rigorous evaluation of current SR evidence on the 
effectiveness, safety and cost-effectiveness of AIT for prevention of allergic sensitization(s) and allergic 
disease(s), 
Outcomes of the SR: 
Primary 
 The development of the first allergic manifestation in healthy individuals, or of a new allergic manifestation 
in those with a previous allergic condition (e.g. development of asthma in patients with atopic 
eczema/dermatitis (AD) or AR, assessed over the short term (< 2 years) or the longer term (≥ 2 years) 
post-AIT 
Secondary 
 The development of new allergic sensitization(s), spreading of allergic sensitization(s) from one allergen to 
other non-related allergen(s), spreading of allergic sensitization(s) at molecular level, from one allergenic 
molecule to other molecules 
 The development of previously non-existent oral allergy syndrome (OAS) 
 Safety as assessed by local and systemic reactions in accordance with the World Allergy Organization’s 
(WAO) grading systems of local and systemic side-effects [28;29]. 
 Health economic analysis from the perspective of the health system/payer as reported in studies 
 
Ensuring appropriate stakeholder involvement 
Participants in the EAACI Taskforce on AIT for Prevention represented a range of countries, with 
various disciplinary and clinical backgrounds, including allergists, primary care physicians, allied 
health professionals, public health practitioners, representatives from patient interest organisations 
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and methodologists who took the took the lead in undertaking the underpinning SR. Additionally, 
producers of immunotherapy products were given the opportunity to review and comment on the draft 
guidelines as part of the peer review and public comment process. The Taskforce members 
considered these comments and revised the Guideline, where appropriate. 
Systematic reviews of the evidence 
The initial full range of questions that were considered important were rationalized through several 
rounds of iteration to agree on one key overarching question: “What is the effectiveness, safety and 
cost-effectiveness of AIT for prevention of allergic disease and sensitization in all populations?”. This 
was then pursued through a formal SR of the evidence by independent methodologists as previously 
published [25;30]. We continued to track evidence published after our SR cut-off date October 31, 
2015 and, where relevant, studies were considered by the Taskforce chairs and members.  
Formulating recommendations 
We graded the strength and consistency of key findings from the SR and meta-analysis, using a 
random-effects model to take into account the heterogeneity of findings [25] to formulate evidence-
based recommendations for clinical care, using an approach that was adapted from that proposed by 
the Oxford Centre for Evidence-Based Medicine (Oxford Centre for Evidence-based Medicine) (Box 3) 
[31]. The adaptation involved providing an assessment of the risk of bias, based on the Cochrane risk 
of bias tool, of the underpinning evidence and highlighting other potentially relevant contextual 
information, formulating clear recommendations and making clear the evidence-base underpinning 
each recommendation. Where the systematic review did not cover the clinical area, we took a 
hierarchical approach reviewing other evidence until we could formulate a recommendation, i.e.: (i) 
other systematic reviews on the subject to see if these provided any clarity on the topic; (ii) RCTs 
within these systematic reviews; (iii) other RCTs known to Taskforce members; and (iv) a consensus-
based approach within the Taskforce. This evidence was graded as described in Box 2 using the 
systematic review data and clearly labelled in the recommendation tables.  In formulating the 
recommendations not only possible beneficial effects, but also any possible disadvantages and harms 
was considered (Table 1). 
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Box 3. Assigning levels of evidence and grade and strength of recommendations (adapted from 
Oxford Centre for Evidence-based Medicine – Levels of Evidence and Grades of 
Recommendations) [31] 
Level of evidence 
Lev l I Systematic reviews, meta-analyses, randomized controlled trials 
Level II Two groups, non-randomized studies (e.g. cohort, case-control) 
Level III One-group, non-randomized studies (e.g. before and after, pre-test and post-test) 
Level IV Descriptive studies that include analysis of outcomes (single-subject design, case-
series) 
Level V Case reports and expert opinion that include narrative literature, reviews and 
consensus statements 
Grades of recommendation 
Grade A Consistent level I studies 
Grade B Consistent level II or III studies or extrapolations from level I studies 
Grade C Level IV studies or extrapolations from level II or III studies 
Grade D Level V evidence or troublingly inconsistent or inconclusive studies at any level 
Strength of recommendations 
Strong Evidence from studies at low risk of bias 
Moderate Evidence from studies at moderate risk of bias 
Weak Evidence from studies at high risk of bias 
Recommendations are phrased according to the strength of recommendation: strong: “is recommended”; 
moderate: “can be recommended”; weak: “may be recommended in specific circumstances” and negative: 
“cannot be recommended” or neutral “cannot be recommended in favor or against” 
 
 
Identification of evidence gaps 
The process of developing this Guideline has identified a number of evidence gaps, which are 
prioritized in Table 2. 
Implementation of the Guideline 
The Taskforce members identified the resource implications, barriers and facilitators to the 
implementation of each recommendation (Tables 3-5), advised on approaches to implementing the 
recommendations and suggested audit criteria that can help with assessing organizational 
compliance with each recommendation (Table 6). 
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Peer-review and public comment 
A draft of this Guideline was externally peer-reviewed by invited external experts in this field from a 
range of organizations, countries and professional backgrounds: Stephen Durham, Peter Eng, Hans 
Jørgen Malling, Antonio Nieto, Zsolt Szepfalusi and Erkka Valovirta. Additionally, the draft Guideline 
were made available on the EAACI website for a three-week period in May 2017 for public review to 
allow a broader array of stakeholders to comment. All feedback was considered by the Taskforce 
members and, where appropriate, final revisions were made in the light of the feedback received.  
Editorial independence and managing conflict of interests 
The production of this Guideline was funded and supported by EAACI. The funder did not have any 
influence on the guideline production process, on its contents, or on the decision to publish. Taskforce 
members’ conflict of interests were declared at the start of the process and taken into account by the 
Taskforce Chairs as recommendations were formulated. Methodologists, who had no conflict of 
interests in this area, checked final decisions about strength of evidence for recommendations.    
Updating the guideline 
EAACI plans to update this guideline using the AGREE II approach in 2022 unless there are important 
advances before then. 
AIT for prevention: Evidence and clinical recommendations 
Overarching considerations 
This Guideline is based on a comprehensive SR evaluating the evidence according to predefined 
well-established methods [25]. As in other SRs, heterogeneity in the populations under study, 
methods employed and outcomes studied made it challenging to interpret the evidence. Factors 
related to the population, such as atopic heredity play a role in the risk of development of allergic 
disease. In addition, children with sensitization and/or early manifestations of atopic diseases e.g. AD 
and food allergy or later manifestation such as AR have a higher risk for development of other allergic 
manifestations such as asthma [17;32]. The age of the population is important as the phenotypic 
expression may change with age and some manifestations may even disappear spontaneously [33]. 
The results of individual studies are difficult to compare because studies have used different 
populations, outcome measures, diagnostic criteria (if any, e.g. the exact definition of asthma, 
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intermittent versus persistent asthma), methods and cut-off values for measuring sensitization. 
Furthermore, the mode of administration and the products used for AIT differ as regards allergens, 
formulation, strength, [34;35] schedules, dose, route of administration and duration of the intervention 
[36]. Additionally, many studies are small without sufficient power and adjustment for confounders. 
Where possible, these factors are taken into consideration in the risk of bias assessment in the SR on 
which this Guideline is based. 
The significant heterogeneity seen in meta-analysis can be explained by the study design, study 
population, products and schedules evaluated. Therefore, an individual product-based evaluation of 
the evidence for efficacy is strongly recommended before treatment with a specific product is initiated 
[16;37]. But, caution is recommended as not all AIT products used currently provide sufficient data to 
support their efficacy in clinical practice. We might consider that a limited class effect can be assumed 
when the same clinical outcomes were used to evaluate clinical efficacy (and safety) of different 
products only if the same route of application, similar dosing schemes and demonstrable comparable 
amounts of relevant allergens and potency were used. However, it should be noted that such 
comparability is also dependent on standardized and validated assays and that a limited class effect 
does not neglect the necessity for product specific clinical studies. 
Using AIT for prevention of development of new allergic disease or sensitization requires use of 
products with a high level of safety, especially in healthy individuals. However, if AIT is indicated due 
to treatment of an already existing allergic disease, and the preventive effect is regarded as an 
additional effect, then the safety profile should be considered in that context.  
Strategies to prevent development of a new sensitization or of a new allergic disease by AIT may vary 
for different populations at different stages in life. Strategies need to be pursued for different 
scenarios, e.g. for those planning pregnancy to take measures such as AIT to reduce the likelihood of 
their child becoming allergic,  healthy infants and young children with early manifestations such as AD, 
older children with manifest allergic disease such as AR, healthy adolescents/adults and 
adolescents/adults with established allergic disease. 
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In order to recommend AIT for the prevention of allergic diseases, evidence is required that there is a 
relevant and substantial beneficial effect on clinical outcomes for the individual. Furthermore, safety 
aspects of the treatment and of the disease to be avoided, quality of life and evaluation of health 
economics should be taken into consideration. Thus, an optimal balance between benefits, harms, 
costs and other possible disadvantages should be achieved (Table 1). 
 
AIT in individuals with AR: Short- and long-term prevention of development of new asthma  
Short-term prevention: The SR [25] identified six RCTs investigating the preventive effect up to two 
years post-AIT on the development of asthma in individuals with AR. These RCTs included three 
SCIT studies (one of low [38], one of moderate [39] and one of high risk of bias [40]), one of moderate 
risk of bias on oral AIT [41] plus one of high [42] and one moderate risk of bias SLIT study [34]. Three 
of these [38;39;41] were small studies with a trend towards less development of asthma in the AIT 
group but no significant differences. The remaining three studies [40;42;43] showed a significant 
reduction of the development of asthma in the AIT groups as compared to the control groups. The SR 
and meta-analysis [25] demonstrated a significant preventive effect of AIT on the development of 
asthma up to two years post-AIT in patients with AR. Subgroup analyses showed that AIT with either 
SLIT or SCIT was beneficial for those aged <18 years but not ≥18 years and for pollen AIT. For HDM 
AIT the groups were so small that there was a non-statistically significant impact despite an OR of 
0.20. There was a high degree of heterogeneity, and therefore the meta-analysis should be 
interpreted with caution although three RCTs demonstrated a statistically significant preventive effect. 
Also the results were supported by two large-scale, real-life, retrospective, non-randomized CBAs 
[44;45], based on German longitudinal prescription databases; both reporting a short-term preventive 
effect of AIT on the progression from AR to asthma.  
Long-term prevention: For the long-term preventive effect, i.e. two or more years post-AIT, the SR 
[25] identified two high risk of bias SCIT RCTs [46;47] in patients with AR. Both showed a significantly 
lower risk for developing asthma in the SCIT groups as compared to the controls, up to seven years 
post-AIT [40;46;48], and two years post-AIT [47]. A large recently published low risk of bias RCT 
(GAP) [49;50]  explored the effect of a three-year course of SLIT tablets on the prevention of asthma 
in 812 children with AR and grass pollen allergy. This study [50] failed to demonstrate the preventive 
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effect of AIT on the development of asthma as defined by very strict a priori criteria including 
reversibility to beta-2-agonists (OR=0.91; 95%CI [0.58 to 1.41])[49;50] two years post-AIT. However, 
the number of subjects with asthma symptoms or asthma medication usage (secondary efficacy 
parameter) was significantly lower in the SLIT group compared to the placebo group at the end of the 
five-year trial period (OR 0.66; 95%CI 0.45 to 0.97; P<0.036), during the two-year post-AIT follow-up 
and during the entire five-year trial period. Also AR symptoms were significantly reduced during the 
entire 5 year trial period. In addition, it appeared that this preventive effect was strongest for the 
youngest children [50]. Two high risk of bias non-randomized studies including one with grass pollen 
SCIT [22;23] and one with HDM SCIT [51] in children with AR also suggested a long-term effect.  As 
published in the SR [25], the meta-analysis showed no overall evidence of reduction in the long-term 
(i.e. at least two years post-AIT) risk of developing asthma, but there was a high degree of 
heterogeneity so the result should be interpreted with caution. Furthermore, the negative result was 
due to one RCT with very strict diagnostic criteria for primary outcome (GAP) in which there was an 
effect when asthma symptoms and/or medication was considered [50]. However, some suggest that 
there is a long-term preventive effect on the development of asthma symptoms and the use of asthma 
medication though further confirmatory studies are needed. 
Thus, there is a question about which asthma outcome parameter is most relevant – a diagnosis 
based on demonstrated reversibility or on symptoms and medication use. There is an urgent need to 
define and standardise the optimal clinical asthma outcomes that should be used in future clinical 
trials. 
Indication for AIT for treatment and prevention in patients with AR 
The RCTs included in the above evaluation of asthma prevention in subjects with AR [40;42;43;46;48-
50] included patients with a history of AR and the need for medication combined with documented 
pollen allergy for at least one previous season. Yet, there is no description on AR severity 
(mild/moderate/severe) or stratification (intermittent/persistent) in these prevention trials, and thus 
these subjects may have had a milder disease than those included in studies on efficacy of AIT. 
However, based on baseline descriptions of the populations in these studies [40;42;43;46;48-50], it is 
reasonable to assume that most of the patients included had persistent symptoms. 
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As discussed in another manuscript on AIT for AR of this EAACI AIT Guideline series [10] [52], many 
patients with AR and pollen allergy benefit from AIT in reducing AR symptoms and need for 
medication. Thus, AIT is recommended for treatment of patients with moderate-to-severe pollen 
induced AR if not optimally controlled on antihistamines and nasal corticosteroids [52] 
None of the studies on prevention of development of asthma in AR included preschool children and 
therefore no recommendations can currently be made in favor of or against AIT  for this age group for 
prevention. 
Based on an objective and clinical evaluation of the current published evidence for AIT preventive 
effects and considering the potential harmful effects, disadvantages and costs associated with the use 
of AIT, these seem to be outweighed by the beneficial effects for this group of patients (Table 1) 
ultimately resulting in a favorable risk benefit profile. 
Thus, there is moderate-to-high quality evidence indicating that AIT (SCIT or SLIT) can be 
recommended for short-term prevention up to two years post-AIT of asthma in children/adolescents 
with moderate/severe AR and pollen allergy who are sub-optimally controlled despite appropriate 
pharmacotherapy, and there are data suggesting that this benefit persists after two years post-AIT as 
regards asthma symptoms and medication use (Table 3). AIT may even be considered in patients 
with milder AR, as AIT might modify the natural disease history, including the long-term effect in AR 
and the preventive effect regarding the development of asthma, qualities which could never be 
attributed to current pharmacotherapy.  
The indication and initiation of AIT should always be preceded by a discussion with the patient / family 
considering the possible benefits, harms, disadvantages, costs, preferential route  of AIT (SCIT vs 
SLIT) based on the individual patient’s profile, preferences and considerations for future AIT 
adherence.  Using AIT for preventive purposes should include all normal safety recommendations as 
for treatment of AR as indicated in the corresponding Guideline on AIT for AR in this EAACI AIT 
Guideline series [52]. 
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Which products and schedules for AIT asthma prevention in individuals with AR should be 
used? 
The products, doses and AIT schedules used in the AIT prevention trials vary. According to the 
subgroup analysis in the SR [25] it appears that SCIT and SLIT are both effective, and that a three-
year AIT course is preferable to a shorter course. The studies that have demonstrated a preventive 
effect used three-year courses of continuous AIT. 
The SR [25] did not compare different AIT products, SLIT drops versus tablets or pre/co-seasonal 
versus perennial AIT. However, according to the results from two lower quality, real-life non-
randomized, controlled before-after AIT treatment studies based on large German longitudinal 
prescription databases [44;45], it seems that SCIT [45] and grass pollen SLIT tablets [44] with natural 
allergen extracts have a preventive effect on the progression from AR to asthma, and that AIT for 
three or more years tended to have a stronger preventive effect than AIT for less than three years. 
Further high-quality RCTs and real-life studies are recommended to objectively confirm this.  
Since the indication for AIT for prevention of asthma is linked to the indication for treatment of AR, the 
products, schedules and doses used should be proven effective for AR with the relevant allergen 
product. Therefore, only those products registered and with the indication for AR (e.g. pollen allergy at 
present and maybe HDM in the future) should be considered for use in allergy prevention. 
AIT in individuals with AD: Short- and long-term preventive effects 
The SR [25] identified one moderate risk of bias RCT investigating the effects of 12 months of daily 
SLIT with a mixture of HDM, cat and Timothy grass allergens on the prevention of asthma and new 
sensitizations in children with AD and sensitization to one or more food allergens [53]. The 
investigators included the absence of a difference between active/placebo groups in early 
immunological changes, i.e. specific IgE/IgG antibodies and associated TH-cell responses, as a 
stopping rule, since this was regarded an indication of whether the treatment was delivering sufficient 
allergen transmucosally to trigger immunological recognition by the infant mucosal system. As these a 
priori immunological changes were not met, recruitment was interrupted and the trial reduced to a 
pilot study status. After 48 months of follow-up, there were no differences in asthma prevalence 
between the two groups [53]. 
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Based on this study, we cannot currently make any recommendations in favour of or against AIT for 
the prevention of the development of a first allergic disease in individuals with AD at present (Table 4) 
and more studies are needed. 
AIT for prevention of allergy in the offspring of allergic individuals 
This topic was not included in the protocol or in the SR. However, we found one recent case-control 
study of high risk of bias comparing 194 children of parents completing AIT at least nine months 
before birth with 195 controls [54]. This study found that the odds ratios of developing any allergic 
disease and asthma was significantly lower in children with at least one allergic parent after AIT 
compared with those having allergic parents who did not receive AIT (odds ratio: 0.73, 95% 
confidence interval 0.59-0.86). The authors hypothesized that AIT in allergic parents might reduce the 
risk of allergies in their offspring, but this requires further investigation. 
Based on the very scarce and very low quality evidence, we cannot currently make any 
recommendations in favour of or against AIT for allergic adults for prevention of allergic disease in 
their offspring (Table 5). 
AIT in healthy individuals: Short- and long-term prevention of development of new allergic 
disease  
Two RCTs, one of low [55] and one  of high risk of bias [56], investigated the possible effect of AIT in 
healthy individuals on the risk for development of their first allergic disease. The large  low risk of bias 
study [55] found no preventive effect of oral HDM AIT on AD, wheeze and food allergy among infants 
with a family history of allergic diseases, whereas the small high risk of bias study [56] reported a 
reduced risk of developing pollinosis among asymptomatic adults sensitized to Japanese cedar pollen 
in the SLIT group. Data from these two trials [55;56] are not comparable. No data on a long-term 
preventive effect were identified. Based on these results from the SR [25] there is currently no good 
evidence to recommend use of AIT for the prevention of a first allergic disease in healthy individuals 
(Table 5) 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
AIT for the prevention of the development of new allergic sensitization 
Short-term effects: The SR identified three low risk of bias RCTs [55;57;58], one moderate [59] and 
two high risk of bias [42;60] RCTs investigating the short-term effects of AIT on the risk of developing 
new sensitizations. One low risk of bias RCT [55] on oral HDM AIT for healthy infants at high risk of 
developing allergic disease found a significant reduction in sensitization to any common allergen (e.g. 
HDM, grass pollen, cat, peanut, milk and egg) in the active group compared with the placebo group at 
the end of the trial, but no difference in HDM sensitization [55]. The other two low risk of bias RCTs 
found no effect of SLIT in adult patients allergic to peach [57] post-AIT and after SLIT with grass 
pollen or HDM extract in mono-sensitized children [58]. Three additional RCTs of moderate to high 
risk of bias [42;59;60] found a significantly lower incidence of new sensitizations among children and 
adults with AR treated with SLIT [42;60] and SCIT [59] as compared to controls.  
Thus, these RCTs of varying quality with varying allergens and formulations showed inconsistent 
results. Meta-analysis showed an overall reduction in the risk of allergic sensitization but the 
sensitivity analyses, excluding the two high risk of bias studies by Marogna [42;60], failed to confirm 
this risk reduction [25]. Due to the high degree of heterogeneity, the results from the meta-analysis 
should be interpreted with caution.  
The inconsistent evidence found in RCTs was also reflected in the included high risk of bias CBA 
studies with three finding a lower occurrence of new sensitizations among AIT treated subjects 
compared with controls [61-63], one reporting higher occurrence in the AIT group compared with 
controls [64] and three studies reporting no differences between groups [65;66] [67]. 
Long-term effects: As regards the long-term (i.e. at least two years post-AIT) effects on prevention of 
new sensitivities the SR identified one moderate [68] and one high risk of bias RCT [69] showing no 
preventive effect of SCIT among children with moderate-to-severe asthma followed into adulthood 
[68] and SCIT in adults with AR three years post-AIT [69]. Another high risk of bias RCT [47] found 
that patients with AR treated with HDM SCIT less frequently developed new sensitizations compared 
with controls two years post-AIT [47]. 
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Thus, there is no good evidence for a reduction in the long-term risk of allergic sensitization. 
The seven high risk of bias CBAs investigating long-term preventive effects of AIT produced 
inconsistent results, one found no difference [70], four showed reduced onset [22;62;71-73] and one 
found a significantly higher occurrence of new sensitization among AIT treated compared with 
controls [74]. 
 
The development of new sensitizations may impose a higher risk for the development of further 
symptomatic allergies suggesting that it might be relevant to prevent the development of new 
sensitizations. However, this has not been investigated sufficiently. A subgroup analysis in the SR [25] 
showed a tendency towards an effect in children and adolescents after three years of AIT, supporting 
the rationale of the clinical effect. 
Thus, there is currently no good evidence to recommend the use of AIT for either short- or long-term 
prevention of development of new sensitizations in healthy individuals, children with atopic 
predisposition (Table 5), children with AD / food allergy (Table 4) or in children and adults with AR / 
asthma (Table 3). Some positive data though suggests that this may be a good focus for future high 
quality trials. 
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Table 1. Benefits and harms / disadvantages of AIT as preventive treatment in different populations 
Population Benefits Harms / disadvantages 
Healthy +/-  sensitization Possible preventive effect 
Daily intake of tablets/drops (SLIT/oral) or regular injections (SCIT) for 3 years 
Frequency of visits to the clinic (SCIT) 
Risk for adverse events 
Costs* 
Children with AD Possible preventive effect not documented 
Daily intake of tablets/drops (SLIT/oral) or regular injections (SCIT) for 3 years 
Frequency of visits to the clinic (SCIT) 
Risk of adverse events 
Costs* 
Patients with AR 
Documented beneficial effect on symptoms 
and reduction in medication on short - and 
long-term 
Possible preventive effect on development 
of asthma 
Daily intake of tablets/drops (SLIT/oral) or regular injections (SCIT) for 3 years 
Frequency of visits to the clinic (SCIT) 
Risk for adverse events 
Costs* 
* Costs should be evaluated in relation to potential direct and indirect costs related to the development of an eventual allergic disease and other 
comorbidities 
AIT: Allergen immunotherapy; AD: Atopic dermatitis / eczema; AR: Allergic rhinitis / rhinoconjunctivitis 
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Table 2. Gaps in the evidence 
Gaps Plan to address Priority 
AIT for prevention of asthma in children with AR due to grass pollen -  long term effects  
Long-term follow up of RCTs 
Further evaluation of GAP trial 
High 
AIT for prevention of asthma in children with AR due to HDM RCTs* High 
Optimal age for introduction of AIT for prevention RCTs* High 
Optimal duration of AIT for prevention RCTs* High 
Optimal product, administration form, dose and schedule of AIT for prevention RCTs* and high quality real life studies High 
Evaluation of influence of AIT for prevention on Qol in different age groups Qol as outcome in RCTs* High 
AIT for prevention of AR / asthma in children and adults with AD / food allergy RCTs* Medium 
Evaluation of health economics of AIT for prevention Cost-effectiveness analysis of RCT Medium 
Evaluation of adherence in AIT for prevention in different age groups Adherence measured in RCTs and real life studies Medium 
Evaluation of acceptability of AIT for prevention in different age groups RCTs* Medium 
AIT for the prevention of new allergic sensitizations 
 spreading from one allergen to related and unrelated allergen(s) 
 spreading at molecular level, from one allergenic molecule to other molecules 
RCTs* Medium 
AIT for prevention of the Oral Allergy Syndrome RCTs* Low 
AIT for prevention of first allergic disease RCTs* Low 
* Apart from new RCTs, published clinical data can be reviewed, raw data can be reanalyzed and blood samples can be analyzed further to provide new data 
AIT: Allergen immunotherapy; AD: Atopic dermatitis / eczema; AR: Allergic rhinitis / rhinoconjunctivitis; HDM: house dust mites 
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Table 3. AIT for prevention: recommendations for school-age children, adolescents and adults with allergic rhinitis (AR) or asthma 
Recommendations for individuals with manifest 
allergic disease(s), e.g. allergic rhinitis 
Evidence 
level 
Grade of 
recommendation 
Strength of 
recommendation  
Other considerations Key references 
In children and adolescents with AR and grass/birch 
pollen allergy, who are sub-optimally controlled despite 
appropriate treatment with antihistamines / nasal 
corticosteroids, a 3 year course of AIT (SCIT or SLIT) 
can be recommended for the short-term (i.e. < 2 years 
post AIT) prevention of the onset of asthma in addition 
to the sustained effect on AR symptoms and 
medication use. 
I A 
Moderate recommendation: 
Based on consistent 
significant results from 2 
moderate [41;43] and 2 high 
risk of bias [40;42] RCTs and 
some CBA studies 
The indication should be 
discussed with the 
patients / families 
including the asthma 
preventive effect as well 
as the effect on AR and 
risk of adverse effects, 
costs and preferences 
Möller1986 [41], 
Möller2002 [40], 
Novembre 2004 [43], 
Marogna 2008 [42], 
Kristiansen 2017 [25] 
In children and adolescents with AR and grass/birch 
pollen allergy, no recommendation can currently be 
made in favor of or against the use of AIT (SCIT or 
SLIT) for the long-term (≥ 2 years post AIT prevention 
of the onset of asthma as diagnosed by symptoms 
combined with demonstrated reversibility  
I B 
Weak recommendation: 
Based on consistent results 
from 2 high risk of bias RCTs 
[46] [47], non-significant 
results from low risk of bias 
RCT [50], and the meta-
analyses being not significant 
due to the latter study 
In the Valovirta 2017 [50]  
study no effect on the 
primary asthma outcome 
using a restrictive 
defintion of asthma based 
on demonstration of 
reversibility. More data is 
needed 
Jacobsen 2007 [46], 
Song 2014 [47], 
Valovirta 2017 [50], 
Kristiansen 2017 [25] 
 
In children and adolescents with AR and grass/birch 
pollen allergy, the use of AIT (SCIT or SLIT) may be 
recommended for the long-term (≥ 2 years post AIT 
prevention of the onset of asthma symptoms and 
medication use 
I B 
Weak -moderate 
recommendation: Based on 
consistent results from 2 high 
risk of bias RCTs [46] [47] 
and secondary outcomes in 1 
low risk of bias RCT [50], 
In the Valovirta 2017 [50]  
study a significant 
preventive effect on the 
secondary outcomes 
asthma symptoms and 
medication was found. 
More data is needed 
Jacobsen 2007 [46], 
Song 2014 [47], 
Valovirta 2017 [50], 
In children and adolescents with AR and allergy to 
house dust mites or other allergens except for 
birch/grass pollen, no recommendation can currently 
be made in favor of or against the use of AIT (SCIT or 
SLIT) for the short-term (i.e. < 2 years post AIT) or 
long-term (i.e. ≥ 2 years post AIT) prevention of the 
I B 
Weak recommendation: 
Based on inconsistent results 
from 1 high [42] and 1 low 
risk of bias RCT [38]  
Only HDM, parietaria and 
mix of these and 
grass/birch pollen 
investigated. More data is 
needed 
Marogna 2008 [42], 
Crimi 2004 [39], 
Grembiale 2000 [38], 
Kristiansen 2017[25] 
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onset of asthma  
In adults with AR and house dust mite or pollen allergy, 
no recommendation can currently be made in favor of 
or against the use of AIT (SCIT or SLIT) for the short-
term (i.e. < 2 years post AIT) or long-term (i.e. ≥ 2 
years post AIT prevention of the onset of asthma  
I B 
Weak recommendation: 
Based on 1 small moderate 
risk of bias study [39] 
Only SCIT with Parietaria 
Judaica investigated. 
More data is needed 
Crimi 2004 [39] 
In children or adults with AR and/or asthma, AIT 
cannot currently be recommended for the prevention of 
new sensitizations,  
I B 
Weak recommendation: 
Based on inconsistent results 
from 4 high [42;47;60;69], 2 
moderate [59;68] and 3 low 
risk of bias [55;57;58] RCTs 
 
Marogna 2004 [60], 
Marogna 2008 [42], 
Dominicus 2012 [69], 
Song 2016 [47], 
Pifferi 2002 [59], 
Limb 2006 [68],  
Garcia 2010 [57], 
Szepfalusi 2014 [58], 
Zolkipli 2015 [55], 
Kristiansen 2017 [25] 
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Table 4. AIT for prevention: recommendations for individuals with early life atopic manifestations, e.g. atopic dermatitis/eczema (AD) or food 
allergy 
 
 
 
 
 
 
  
Recommendations for individuals with early atopic 
manifestations 
Evidence 
level 
Grade of 
recommendation 
Strength of 
recommendation 
Other 
considerations 
Key 
references 
In children with AD, AIT no recommendations can currently be made 
in favor of or against the use of AIT for the prevention of onset of later 
allergic manifestations 
I B 
Weak recommendation: 
Based on 1 small moderate 
risk of bias study [53] 
 
Holt 2013 
[53] 
In individuals at all ages with other early atopic manifestations e.g. 
food allergy, no recommendations can currently be made in favor of 
or against the use of AIT for the prevention of onset of other allergic 
manifestations  
V D Expert opinion. No studies 
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Table 5. AIT for prevention: recommendations for healthy individuals 
Recommendations for healthy individuals all ages 
Evidence 
level 
Grade of 
recommendation 
Strength of 
recommendation  
Other 
considerations 
Key 
references 
In adult allergic patients, no recommendations can 
currently be made in favor of or against the use of AIT for 
the prevention of onset of allergic diseases in their 
offspring 
IV-V D 
Weak recommendation: 
Based on results from 1 
high risk of bias study [54]  
 
Bozek, 
2016 [54] 
In healthy individuals with or without sensitization, AIT 
cannot currently be recommended for prevention of onset 
of allergic diseases  
I A 
Weak recommendation: 
Based on 1 low [55] and 1 
high risk of bias RCTs [56] 
One RCT with 
infant and one 
with adult 
population 
Zolkipli 
2015 [55], 
Yamanaka 
2015 [56] 
In healthy children, AIT cannot currently be recommended 
for the prevention of new sensitizations 
I B 
Weak to moderate 
recommendation: Based on 
results from 2 low risk of 
bias  RCTs [55] [58] 
One RCT with 
infant and one 
with preschool 
population 
Zolkipli 
2015 [55], 
Szepfalusi 
2014 [58] 
In healthy adults, no recommendations can currently be 
made in favor of or against the use of AIT for the 
prevention of new sensitizations 
V D Expert opinion. No studies 
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Table 6: Recommendations for individuals with allergic rhinitis: Implementation 
Prevention of development of 
asthma in patients with AR 
Barriers to implementation Facilitators to implementation Audit criteria Resource implications 
 In children and adolescents with 
AR and grass/birch pollen 
allergy who are sub-optimally 
controlled despite appropriate 
treatment with antihistamines / 
nasal corticosteroids, a 3 year 
course of AIT (SCIT or SLIT) 
can be recommended for short-
term (i.e. < 2 years post AIT) 
prevention of the onset of 
asthma in children with daily 
symptoms and need for 
medication 
 Lack of recognized policy in Europe 
about allergies and their treatment. 
 Failure to recognize manifestations 
in primary care.  
 Lack of knowledge amongst 
patients, caregivers and primary 
care professionals about the 
benefits of AIT. 
 Lack of communication specialists / 
primary care interface or specific 
referral criteria primary care. 
 Lack of agreed clinical pathways  
 Lack of access to AIT 
 Unavailability of AIT  
 No reimbursement  
 Costs of travel and time of work for 
patients and caregivers 
 Concerns about side-effects and 
safety of especially SCIT 
 Lack of health economics data 
 Government and European 
policy on allergy.  
 Reimbursement of AIT 
 Accessible education and 
training in allergy primary care. 
 Agreed competencies in allergy 
for primary care and allied 
health workers for shared care 
protocols.  
 Information amongst patients, 
caregivers and healthcare 
professionals about the 
benefits of AIT. 
 Integrated multidisciplinary 
working and service delivery.  
 Timely advice and continuous 
guidance by specialists.  
 Workforce remodeling.  
 Agreed pathways of care with 
cross boundary working  
 
 Proportion of 
potentially eligible 
patients referred 
from primary care 
for a specialist 
assessment 
 Proportion of 
potentially eligible 
patients formally 
considered for 
AIT 
 Identification of 
patients who may 
benefit from AIT. 
Thorough 
investigation of the 
patient including 
proper assessment 
of relevant allergies. 
 AIT need to be 
prescribed, made 
available and 
administered to 
patients. 
 Evaluation of effect 
and eventual AEs 
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Safety 
The safety issues are fully covered by the SR and guideline for AR in this AIT guideline series [10;52]. 
SCIT is occasionally associated with allergic side effects and should therefore be administered in a 
specialist setting. Fatalities are very rare and have not been reported with the use of SLIT. In a recent 
meta-analysis about the efficacy of grass-pollen SLIT tablet by Di Bona et al. [75] seven treatment 
related adverse events requiring adrenaline were reported in the SLIT RCTs, however no episode of 
anaphylaxis was reported. In recent real-life clinical studies of AIT, less severe systemic reactions 
were reported with SLIT than with SCIT, although the overall rate of adverse reactions is similar in 
SCIT and SCIT [76;77]. The safety profile for the present purpose is not regarded as being different 
from AIT for treatment of AR. Due to its better safety profile SLIT might be a better choice for 
prevention than SCIT. 
Summary, gaps in the evidence, future perspectives and implementation 
This Guideline on AIT for prevention of allergy has been developed as part of the EAACI Guidelines 
on Allergen Immunotherapy project. The recommendations in this Guideline are based on a thorough 
SR performed by a group of experienced and independent methodologists and have been developed 
by a multidisciplinary EAACI Task Force representing a range of countries and disciplines and clinical 
backgrounds. 
The Guideline provides evidence-based recommendations for the use of AIT for prevention of new 
allergic disease(s) and new allergic sensitization(s) in all populations. The guideline should assist all 
healthcare professionals as regards evaluation of AIT for prevention of allergic disease /sensitization, 
and when to refer which individuals to further evaluation. The main results are summarized in Box 4. 
The key limitation of this guideline is the heterogeneity and gaps in the underpinning literature. There 
are many areas for which there is no evidence or no high quality evidence; these represent gaps in 
the current evidence (Table 2). Thus, for the preventive effect of AIT in healthy individuals or in 
children with early atopic manifestations such as AD or food allergy as well as for the possible long-
term effect in children with AR, more high quality data are needed. Also, we did not find studies 
related to spreading of allergic sensitization(s) at the molecular level, nor did we identify studies 
exploring the development of new OAS or health economic analyses of AIT used for prevention.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
In addition, there is a lack of evidence as regards patient selection (e.g. optimal age and 
characteristics) for preventive AIT and for the optimal allergen preparation, mode and duration of AIT 
administration; there is a need to define standardized relevant outcomes including asthma and quality 
of life (Qol) for future studies. 
The current evidence does not allow to identify superiority between SCIT and SLIT; therefore, this 
choice depends on availability, patients / family’s’ preferences, safety, costs, routes, schedules and 
patients adherence to the AIT treatment. Only products and regimens proven effective for treatment of 
AR should be used. Currently only products with the indication for treatment of AR can be 
recommended for prevention of asthma in children and adolescents with AR and pollen allergy.  
Based on current evidence, AIT can be recommended for up to two years post-AIT of development of 
asthma in children and adolescents with AR and pollen allergy primarily birch and grass. Some 
studies suggest a long-term asthma preventive effect as regards asthma symptoms and medication 
use, though it has to be further demonstrated if this effect can be extended to  asthma as diagnosed 
by stricter diagnostic criteria. Such a disease-modifying effect after cessation of AIT is not achievable 
with pharmacotherapy. AIT should in particular be considered for those with moderate-severe AR as it 
has been shown to be effective in controlling this condition in addition to the preventive effect on the 
development of asthma [10;52]. Furthermore, some patients with less severe AR may prefer AIT to 
reduce medication use and avoid side effects of other treatments, to obtain long-term efficacy and/or 
to obtain the asthma preventive effect. 
Considerations should be taken when making recommendations for AIT as preventive treatment in 
allergy, as children and adolescents included in the prevention studies did not necessarily fulfil the 
criteria for proper endorsement of AIT for treatment of AR as well as they did not necessarily meet the 
“Allergic Rhinitis and its Impact of Asthma” (ARIA)[9] criteria for moderate/severe AR.  
At present, the indications for AIT for prevention of allergic disease are the same as for treatment of 
AR (i.e. documented IgE-mediated disease caused by the relevant allergens and not sufficiently 
controlled by antihistamines and nasal corticosteroids) [52]. Contraindications are the same as for 
treatment of AR [52]. The asthma preventive effect may in the future downgrade the level of severity 
of AR required before initiation of AIT in children and adolescents with AR and pollen allergy, 
especially grass pollen allergy. Therefore, AIT as a relevant treatment option for children and 
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adolescents up to 18 years of age with less severe AR due to pollen allergy should be further 
investigated and discussed. Currently, there is no high quality evidence to support AIT for prevention 
in HDM allergic patients with AR, but further high quality studies are warranted. 
The products available, and registered for different indications, have varied over time and across 
countries. Therefore, at present we cannot make homogeneous product specific recommendations at 
a European level. In the context of the implementation of this guideline series, we plan to provide 
such recommendations based on the on each national country   availability of the products 
For the implementation of this Guideline (described in Table 6) there is a need to ensure that primary 
care healthcare professionals recognise AIT as a treatment option for some allergic diseases and 
have clear guidelines to aid patient selection for early referral to specialist care [78]. Patients and 
patient organizations need to be aware of AIT as a treatment option. Political awareness should be 
increased to ensure sufficient availability, knowledge, competences, skills and resources in the health 
care system by demonstrating the economic benefits of AIT by proper assessment of its positive 
impact on economic productivity. In addition, methods to overcome problems with adherence should 
be further considered and evaluated. Finally, a plan for monitoring the audit criteria should be part of 
the dissemination and implementation plan, and as new evidence is published these guidelines will be 
updated with appropriate revision of specific recommendations.
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Box 4 Summary 
 A three year course of AIT (SCIT or SLIT) can be considered in children with moderate to  
severe AR and grass/birch pollen allergy, not sufficiently controlled with optimal 
pharmacotherapy, for 
• Treatment of AR with a sustained effect on symptoms and use of medication 
beyond cessation of AIT 
• Short-term (i.e. up to 2 years post-treatment) prevention of the onset of asthma 
in addition to improving the control of AR. Moreover, some studies indicate that 
this asthma preventive effect is maintained over a longer period as evaluated 
by symptoms and medication use.  
• Only AIT products with documented effect in patients with the relevant pollen allergy should 
be used and a product specific evaluation of clinical efficacy and preventive effects is 
recommended 
• Before initiating AIT the possible benefits including the beneficial effects on controlling AR 
symptoms, disadvantages, potential harms, patients’ preferences (SCIT or SLIT-tablets/ 
SLIT-drops), patients’ adherence to treatment and costs should be discussed with the 
patient / family on an individual basis 
 There is an urgent need for more high-quality clinical trials on prevention in AIT and more 
high quality evidence. 
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Box 5 Key messages for primary care about referral to allergy services 
 AIT have a role in delaying/preventing progression from seasonal AR/ARC to asthma 
o Primary care teams should consider early referral of children with troublesome AR 
in spite of pharmacotherapy with antihistamine and or nasal corticosteroids for a 
specialist assessment with a view to considering AIT to improve control of AR and 
also simultaneously delay/prevent asthma 
o Patients should be considered as “individuals” during the assessment  to prescribe 
AIT, they all have to be aware of the potential benefits, risks and costs of AIT  
 AIT may be indicated in those individuals with perennial AR on clinical grounds but not only 
for delaying/preventing progression to asthma (this preventive effect needs to have high 
quality evidence) 
 Recommendations cannot currently be made for AIT to prevent: (i) allergic parents who 
would be interested in receiving AIT to prevent allergy in their offspring; (ii) healthy 
infants/children; (iii) infants/children with AD and/or food allergy 
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